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Abstract
Introduction: Cardiac involvement is one of the chief complications considerably 
contributing to the morbidity and mortality of patients with systemic autoimmune 
diseases. Anticardiolipin antibody is a marker of elevated myocardial infarction risk and it 
also predicts post cardiac intervention risk. In the current study, we aimed to evaluate the 
association between anticardiolipin IgM and IgG levels and atherosclerotic involvement 
of coronary arteries.
Methods: Patients with acute coronary syndrome admitted to a military hospital were 
included in the study. Patients were categorized to military personnel and non-military 
personnel. Laboratory data including lipid profile, blood sugar, anticardiolipin IgM and 
anticardiolipin IgG were verified. Existence and the extent of Coronary Artery Disease 
(CAD) were defined according to angiographic findings. The relationship between 
anticardiolipin antibody levels and the number of vessels were evaluated.
Results: According to our sample population calculation, we performed the study on a 
total of 92 patients. Measurement of both anticardiolipin antibodies (IgM and IgG) in 
military personnel and non personnel patients showed no significant difference. In both 
military personnel and non personnel groups, there was a significant association between 
anticardiolipin IgM and IgG levels and number of coronary arteries with significant 
stenosis. The C Reactive Protein (CRP) level was significantly higher in military personnel.
Conclusions: According to the study results, anticardiolipin antibody levels were the same 
in both military personnel and non personnel. Also systolic and diastolic blood pressures 
were not significantly different in both groups. Increased CRP level in military personnel 
may be a warning signal about the possibility of premature CAD in this population, hence 
aggressive risk factor modification is recommended. Paradoxically lipid profile and FBS 
levels were more favorable in military personnel, which indirectly reflects their higher state 
of physical activity.
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INTRODUCTION
Atherosclerosis is a multifactorial process, which initiates in 
early life but presents clinically later in life. Atherosclerosis 
is progressively more considered an immune-mediated pro-
cess. Epidemiological studies revealed an increase of cardio-
vascular events in patients affected by systemic autoimmune 
diseases. All the anatomical heart structures can be affected, 
and several pathogenic mechanisms have been reported [1].
Antiphospholipid Syndrome (APS) is a disorder that man-
ifests clinically as recurrent venous or arterial thrombosis 
and/or fetal loss. Antiphospholipid (APL) antibodies are 
a group of antibodies directed against epitopes on plasma 
proteins that are uncovered by binding of these proteins to 
anionic phospholipids on plasma membranes. Character-
istic laboratory abnormalities in APS, include persistently 
elevated levels of antibodies directed against membrane an-
ionic phospholipids (i.e. Anticardiolipin [ACL] antibody, 
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antiphosphatidylserine) or their associated plasma proteins, 
predominantly beta-2 glycoprotein I (apolipoprotein H), or 
evidence of a circulating anticoagulant [2-5].
Anticardiolipin antibody is a member of autoantibodies, which 
directly acts against protein- phospholipid complex. Elevated 
levels of these antibodies are associated with a clinical syn-
drome in which venous and arterial thrombosis occurs [6-9]. 
In addition to antiphospholipid antibody syndrome, anticardi-
olipin level elevates in a variety of autoimmune diseases espe-
cially in SLE [10]. A subset of people with no apparent autoim-
mune disease, have elevated anticardiolipin levels.
Early findings about the clinical importance of anticardiolip-
in antibodies came from SLE patients [11]. In SLE, patients 
with higher titers of anticardiolipin antibody had more vas-
cular events including arterial thrombosis [12]. Interestingly, 
14% of patients with thrombotic brain ischemia had marked 
elevation of anticardiolipin antibody [13, 14]. Anticardiolip-
in antibody is a marker of elevated myocardial infarction risk 
and it also predicts post cardiac intervention risk [15].
These observations support the possible role of autoimmu-
nity in the genesis of atherosclerosis that may have clinical 
or subclinical features. The clinical edge of this phenomenon 
is Coronary Artery Diseases (CAD), while early endothelial 
dysfunction, abnormalities of circulation or atherosclerotic 
plaques, detected by different imaging techniques, identifies 
the subclinical atherosclerosis expression. According to dif-
ferent reports, traditional risk factors were not different in 
APS and in the general population [16]. In agreement with 
these findings, APS patients have an increased rate of car-
diovascular incidents: myocardial infarction appears at same 
stage of the disease in up to 5.5% and is the presenting mani-
festation in 2.8% of APS patients [17].
In spite of the mentioned studies, some researchers have 
shown that there is no robust association between anticardi-
olipin levels and cardiovascular risk. In addition, evidence for 
the relationship between anticardiolipin antibody and ath-
erosclerosis is limited.In the current study, we aimed to eval-
uate the association between anticardiolipin IgM and IgG 
levels and atherosclerotic involvement of coronary arteries 
with an angiographic study.
METHODS
This study had a cross sectional design in order to evaluate the 
relationship between anticardiolipin level and the extent of cor-
onary artery disease. Patients with acute coronary syndrome 
admitted to 502 military hospitals of the Islamic Republic of 
Iran were included in the study. Patients were categorized to 
two groups. The first group comprised of military personnel, 
who were admitted with Acute Coronary Syndrome (ACS) di-
agnosis and underwent coronary angiography to delineate the 
coronary anatomy, this group was defined as our case group. 
The second group composed of non military patients, who 
were admitted to the 502 military hospitals with the diagnosis 
of ACS and underwent coronary angiography, this group was 
defined as the control group. All patients with ACS and the 
high risk criteria became candidates of coronary angiography, 
according to our current standard guidelines. Exclusion crite-
ria included any active or chronic inflammatory disease, acute 
or chronic infectious disease, known autoimmune disease and 
consumption of certain drugs including phenothiazin, hydral-
azine, procainamide and prednisone within the past year. To 
determine the sample population we relied on data obtained 
by the study of Eber et al [18].
Demographic, clinical and paraclinical data were gathered 
in a questionnaire, according to the medical records of the 
patients. Clinical variables including systolic and diastolic 
blood pressures were recorded. Laboratory data including 
lipid profile, blood sugar, anticardiolipin IgM and anticardio-
lipin IgG were verified. Existence and the extent of CAD was 
defined according to the angiographic findings. Significant 
CAD was defined as the existence of more than 50% diam-
eter luminal stenosis of the coronary arteries. Once concent 
was provided by the patients, 5 cc of blood was drained extra 
to the routine blood sampling to measure the anticardiolipin 
level with the Enzyme Linked Immunosorbent Assay (ELI-
SA). The study protocol was approved by the medical ethics 
committee of the Islamic Republic of Iran military force and 
all procedures were designed according to the declaration of 
Helsinki. After providing detailed oral information to partici-
pants, written informed consent was obtained from each par-
ticipant. The study was intended to be triple blind. Patients, 
laboratory technicians, physicians in charge of angiography 
and the statistics specialist were all unaware of the aims of 
study and about the importance of comparison between mil-
itary personnel and non personnel patients.
To assess variables, quantitative results were declared in the 
form of mean +/- standard deviation and qualitative vari-
ables were stated with their percentages. In order to evaluate 
the relationship between the anticardiolipin antibody levels 
(IgM and IgG) and the number of vessels with significant ste-
nosis in angiography, we used One-way Analysis of Variance 
(ANOVA) statistical test.
In order to document the association between employment 
in the military service and anticardiolipin antibody level and 
number of involved coronary arteries, we used the Cumula-
tive Logit Modeling statistical test. To analyze the results, the 
SPSS software version 9.1 and SAS software version 16 were 
used. For stating the statistical significance, p values of level 
less than 0.05 were considered statistically meaningful.
RESULTS
According to our sample population calculation, we performed 
the study on a total of 92 patients (46 patients in military per-
sonnel group and 46 patients in the nonmilitary personnel 
group). All patients in the military personnel group were male 
while only 58.7% of participants in the non military group were 
male. Patients in the military personnel group were significant-
ly younger than the patients in the non-military personnel 
group. There was no significant difference in systolic blood 
pressure in the two groups (Table 1).
In the laboratory findings, C Reactive Protein (CRP) level 
was significantly higher in the military personnel group than 
the non-military personnel. In contrast, military personnel 
had significantly lower total cholesterol and Fasting Blood 
Sugar (FBS) levels and higher high density cholesterol lev-
el (Table 1). Furthermore, 60.9% of military personnel and 
80.3% of non military personnel had no significant stenosis 
of coronary arteries in angiography. Distribution of involved 
vessels and the frequency of left main disease were the same 
in the two groups but the percentage of three vessel disease 
was higher in the military personnel than the non personnel 
(19.6% versus 10.9%) (Table 2).
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Table 1 Demography and Baseline Laboratory Finding of the Patients
Features Military Personnel Non Personnel P value
Male 46 (100) 27(58.7) < 0.001
Age (years) 49.6 ± 5.6 54.4 ± 11.1 0.01
Systolic blood pressure (mmHg) 132.2 ± 17.2 126.0 ± 17.8 0.127
Positive CRP 12 (21.7) 1(2.2) 0.004
ESR (mm/h) 14.3 ± 9.1 16.9 ± 14 0.327
FBS (mg/dL) 102.7 ± 23.4 139.4 ± 20.5 < 0.001
Total cholesterol (mg/dL) 234.9 ± 59.2 265.9 ± 42.5 0.006
Triglyceride (mg/dL) 158.3 ± 35.6 161.5 ± 79.8 0.810
LDL (mg/dL) 119.6 ± 29.3 129.7 ± 39.4 0.187
HDL (mg/dL) 38.5 ± 10.4 32.7 ± 2.5 < 0.001
CRP: C reactive protein; ESR: erythrocyte sedimentation rate; FBS: fasting blood sugar; HDL: high density cholesterol; LDL: low densi-
ty cholesterol
Data are presented as No (%) or mean ± SD
Table 2: Angiography Features of the Patients
Military Personnel Non Personnel P value
Distribution of CAD
LAD 18 (39.1) 18 (39.1) 0.999
LCX 9 (19.6) 11 (23.9) 0.613
RCA 9 (19.6) 11 (23.9) 0.613
Number of vessels with significant stenosis
Normal 28 (60.9) 25 (84.3) > 0.05
1 vessel disease 9 (19.6) 7 (15.2) > 0.05
2 vessel disease 0 (0) 9 (19.6) > 0.05
3 vessel disease 9 (19.6) 5 (10.9) 0.014
Left main stenosis 0 (0) 1 (2.2) 0.999
LAD: left anterior desending artery; LCX: left circumflex artery; RCA: right coronary artery Data are presented as No (%)
 
 
Figure 1: Association of Anticardiolipin Antibody IgM and Num-
ber of Coronary Stenosis
Measurement of both anticardiolipin antibodies (IgM and 
IgG) in military personnel and non personnel patients 
showed no significant difference. Consequently, employ-
ment in the military service does not alter the level of anti-
cardiolipin antibodies. Anticardiolipin IgM antibody level in 
military personnel and military non personnel patients were 
1.973.04 ± MPL units and 1.94 ± 2.66 MPL units, respective-
ly. Anticardiolipin IgG antibody level in military personnel 
and military non personnel were 2.55 ± 4.14 GPL units and 
2.71 ± 3.88 GPL units, respectively. In both military person-
nel and non personnel groups, there was a significant asso-
ciation between anticardiolipin IgM levels and number of 
coronary arteries with significant stenosis (Fig 1).
Anticardiolipin antibody IgM level in patients with normal 
coronary arteries in military personnel and non military per-
sonnel were 1.4 and 2.4 MPL units, respectively. The IgM 
antibody level with single vessel coronary artery disease in 
military personnel and non military personnel were 3.1 and 
2.9 MPL units, respectively. In patients with two vessel coro-
nary artery disease, IgM antibody level in military personnel 
and military non personnel patients were respectively 3.6 
and 3.3 MPL units. Finally three vessel coronary artery in-
volvement in military personnel and non personnel groups 
had IgM antibody level of 4.1 and 3.8 MPL units, respectively 
(P < 0.05). In addition, in both military personnel and non 
personnel groups, there was a significant association between 
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anticardiolipin IgG levels and number of coronary arteries with significant stenosis (Table 3).
Table 3: Anticardiolipin IgG Antibody Level in Patients Who Underwent Angiography
IgG level (GPL) Military Personnel Non Personnel P value
Normal Coronary arteries 1.5 ± 0.1 3.2 ± 0.2 < 0.05
1 vessel disease 3 ± 0.2 3.6 ± 0.3 < 0.05
2 vessel disease 4.1 ± 0.5 3.9 ± 0.3 < 0.05
3 vessel disease 5.4 ± 0.3 4.9 ± 0.5 < 0.05
Data are presented as mean±SD
DISCUSSION
Some novel risk factors that could contribute to atherosclero-
sis development have been reported recently. These include 
inflammatory markers, including CRP, fibrinogen, interleu-
kin-6, CD40/CD40L, adhesion molecules, and immuno-
logical factors including anticardiolipin (ACL), anti-β2GPI, 
anti-oxLDL and anti-HSP antibodies. Several autoantibodies 
are associated with atherosclerosis and its manifestations in 
humans [19].
Antiphospholipid Syndrome is a prothrombotic state char-
acterized by recurrent arterial and venous thrombosis, recur-
rent pregnancy loss, and the presence of circulating antiphos-
pholipid antibodies. Thrombophilia may be associated with 
premature atherosclerosis, and accelerated atherosclerosis 
was suggested as an additional clinical feature of APS. This 
pathological process may be mediated by direct proinflam-
matory and procoagulant activity that APLs exert on en-
dothelial cells or indirectly, via the inflammatory/immune 
mechanisms that have been implicated in autoantibody-me-
diated thrombosis [20]. Veres et al. showed a correlation be-
tween serum levels of ACL and anti-β2GPI antibodies and 
the incidence and severity of acute coronary syndrome, MI 
and stroke [21]. Therefore, non-traditional risk factors such 
as antibodies seem to be involved in APS-associated athero-
genesis. In vitro, APL accelerates the process of plaques for-
mation, enhancing the macrophages transformation to foam 
cells by oxLDL [22].
The actual frequency of APS in the general population is un-
known. One to 5% of healthy individuals have APL antibod-
ies. Furthermore, ACL antibodies tend to be found more fre-
quently in elderly persons; thus, positive titer results should 
be interpreted with caution in this population. The APL an-
tibodies are found in approximately 30-40% of patients with 
SLE, but only about 10% have APS [23].
Antiphospholipid Syndrome is more common in young to 
middle-aged adults; however, it also manifests in children 
and elderly people. A female predominance has been doc-
umented, particularly for secondary APS. This parallels the 
association of APS with SLE and other connective-tissue dis-
eases, which also have a female predominance [24]. Patients 
with APS are prone to cardiovascular events. Coronary artery 
events and valvular heart disease are common features of this 
syndrome [25]. Consequently, early diagnosis, aggressive 
risk factor modification and proper management may reduce 
the cardiovascular burden in patients with APS. In this study, 
in addition to the measurement of anticardiolipin antibody 
levels and evaluation of their relationship with number of 
coronary artery stenosis, we further explored the differences 
in military and nonmilitary personnel.
According to the study results, anticardiolipin antibody levels 
were the same in both military personnel and non person-
nel patients. Also systolic and diastolic blood pressures were 
not significantly different in both groups. As mentioned in 
the result section, CRP level was higher in the military per-
sonnel group. Chronic inflammation is pivotal in heart dis-
ease; studies have shown that high levels of CRP, measured 
by high-sensitivity CRP (hs-CRP), can be a marker of ath-
erosclerosis. High sensitivity-CRP is an important predictor 
for cardiovascular events, including myocardial infarction, 
cerebrovascular events, peripheral vascular disease and sud-
den cardiac death in individuals without a history of heart 
disease. In patients with acute coronary disease, CRP level 
predicts mortality and cardiac complications [26]. High 
CRP levels portend a worse prognosis in patients with acute 
coronary syndromes. High sensitivity-CRP is also a marker 
of metabolic syndrome [27].
Increased CRP level in military personnel may be a warn-
ing signal about the possibility of premature CAD in this 
population, hence aggressive risk factor modification is rec-
ommended. Paradoxically, lipid profile and FBS levels were 
more favorable in military personnel group, which indirectly 
reflects their higher state of physical activity. In angiography, 
as stated although military personnel had higher frequency 
of coronary artery disease, the difference was not statistically 
significant. The subgroup of patients with three-vessel CAD 
had significantly higher frequency in military personnel. 
Considering the higher CRP level in military personnel, and 
the predictive value of CRP, aggressive modification of CRP 
and inflammatory state in all patients and particularly in mil-
itary personnel seems reasonable [28-31].
 According to the findings of the current article, anticardi-
olipin antibody levels are not different in military and non 
military personnel but in both groups the higher titers of 
antibodies are associated with more extensive CAD. In con-
clusion, in this study we showed the importance and associa-
tion of anticardiolipin antibodies and CRP with the extent of 
CAD. Further research is recommended for exploring these 
issues to target the atherosclerosis process more efficiently.
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